Selonsertib
Drug18 mg tablet administered orally once daily
Other names: GS-4997
NCT Number: NCT02854631
The primary objective of this study is to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (AH).
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2
Medizinische Universitat Graz, Graz, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
18 mg tablet administered orally once daily
Other names: GS-4997
40 mg (4 x 10 mg tablets) administered orally once daily
Selonsertib placebo tablet administered orally once daily
Time frame: Up to Day 28 plus 30 days
An AE was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
Time frame: Day 28
The percentage of participants who died by Day 28 was calculated.
Time frame: Week 8
The percentage of participants who died by Week 8 was calculated.
Time frame: Week 12
The percentage of participants who died by Week 12 was calculated.
Time frame: Week 24
The percentage of participants who died by Week 24 was calculated.
Time frame: Day 28
The percentage of participants with survival at Day 28 using Kaplan-Meier was calculated.
Time frame: Week 8
The percentage of participants with survival at Week 8 using Kaplan-Meier was calculated.
Time frame: Week 12
The percentage of participants with survival at Week 12 using Kaplan-Meier was calculated.
Time frame: Week 24
The percentage of participants with survival at Week 24 using Kaplan-Meier was calculated.
Time frame: Day 28, Week 8, Week 12, and Week 24
The percentage of participants who received a liver transplant by week 24 was calculated.
Time frame: Up to 24 weeks
The occurrence of HRS was confirmed based on the following diagnostic criteria from the International Ascites Club (IAC): 1) Cirrhosis with ascites, 2) Diagnosis of acute kidney injury (AKI) according to the ICA-AKI criteria, 3) Absence of shock, 4) No current or recent treatment with nephrotoxic drugs, and 5) Absence of parenchymal renal disease as indicated by proteinuria >500 mg/day, microhematuria (> 50 red blood cells per high power field) and/or abnormal renal ultrasonography.
Time frame: Up to 24 weeks
The occurrence of bacterial, fungal, or viral infections was recorded. An infection was considered definite in participants with clinical evidence of infection and a positive culture from a normally sterile source (with the exception of spontaneous bacterial peritonitis).
Time frame: Up to 24 weeks
Length of initial hospital stay from first dose date of study drug was calculated for participants who were released from initial hospitalization separately from those who died during their initial hospitalization.
Time frame: Baseline (Day 1) and up to 24 weeks
Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Baseline (Day 1) and up to 24 weeks
Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Baseline (Day 1) and up to 24 weeks
Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Baseline (Day 1) and up to 24 weeks
Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Baseline (Day 1) and up to 24 weeks
Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Baseline (Day 1) and up to 24 weeks
Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Baseline (Day 1) and up to 24 weeks
Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Day 7
The Lille score is a tool used to predict which participants with severe alcoholic hepatitis (AH) were not responding to corticosteroid therapy. It ranges between 0 and 1, with low scores (< 0.16) indicating complete response or positive response to steroids (continue therapy) and high scores (≥ 0.56) indicating no response or poor response to steroids (stop therapy). The Lille score was calculated using baseline factors: age, albumin, total bilirubin, serum creatinine, prothrombin time; and the change in total bilirubin between baseline (Day 1) and Day 7. Lille response was defined as having a Lille score < 0.45.
Time frame: Day 7
The Lille score is a tool used to predict which participants with severe AH were not responding to corticosteroid therapy. It ranges between 0 and 1, with low scores (< 0.16) indicating complete response or positive response to steroids (continue therapy) and high scores (≥ 0.56) indicating no response or poor response to steroids (stop therapy). The Lille score was calculated using baseline factors: age, albumin, total bilirubin, serum creatinine, prothrombin time; and the change in total bilirubin between baseline (Day 1) and Day 7. Lille null response was defined as having a Lille score ≥ 0.56.
Time frame: Day 7
The Lille score is a tool used to predict which participants with severe AH were not responding to corticosteroid therapy. It ranges between 0 and 1, with low scores (< 0.16) indicating complete response or positive response to steroids (continue therapy) and high scores (≥ 0.56) indicating no response or poor response to steroids (stop therapy). The Lille score was calculated using baseline factors: age, albumin, total bilirubin, serum creatinine, prothrombin time; and the change in total bilirubin between baseline (Day 1) and Day 7.
Time frame: Baseline and Day 7 Time Points used to calculate Overall Mortality Risk at Months 2 and 6
The Lille score is a tool used to predict which participants with severe AH were not responding to corticosteroid therapy. It ranges between 0 and 1, with low scores (< 0.16) indicating complete response or positive response to steroids (continue therapy) and high scores (≥ 0.56) indicating no response or poor response to steroids (stop therapy). MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity. A scoring system combining the Lille score at Day 7 and the baseline MELD score was used to calculate the percentage of participants expected to die by Month 2 and by Month 6.
Time frame: Baseline (Day 1) and up to 24 weeks
MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity. Change from Baseline was calculated as the value at endpoint minus the value at Baseline.
Time frame: Baseline (Day 1) and up to 24 weeks
CPT scores are used to assess the severity of cirrhosis. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease
Time frame: Baseline (Day 1) and up to 24 weeks
Baseline Maddrey DF score is a prognostic tool used to determine the next step of treatment based on the severity of AH. Maddrey DF score of < 32 indicates mild to moderate AH and a lower chance of death in the next few months. Maddrey DF score of ≥ 32 indicates severe AH and a higher chance of death in the next few months. The score has no bounds.
Gilead Sciences
Industry
A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06740318
Alcohol-Induced Disorders, Alcohol-Related Disorders
Hvidovre, Denmark
View Trial DetailsNCT05883891
Alcohol-Induced Disorders, Alcohol-Related Disorders
Rome, Roma (provincia), Italy
View Trial DetailsNCT01143246
Alcohol-Induced Disorders, Alcohol-Related Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT02326103
Alcohol-Induced Disorders, Alcohol-Related Disorders
Helsinki, Finland
View Trial Details